Arul M Chinnaiyan

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1793766/publications.pdf

Version: 2024-02-01

526	110,073	264	227
papers	citations	146 h-index	316 g-index

538	538	538	98545
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Development of a Whole-urine, Multiplexed, Next-generation RNA-sequencing Assay for Early Detection of Aggressive Prostate Cancer. European Urology Oncology, 2022, 5, 430-439.	2.6	8
2	A transcriptomic model for homologous recombination deficiency in prostate cancer. Prostate Cancer and Prostatic Diseases, 2022, 25, 659-665.	2.0	9
3	Viral Status Predicts the Patterns of Genome Methylation and Decitabine Response in Merkel Cell Carcinoma. Journal of Investigative Dermatology, 2022, 142, 641-652.	0.3	9
4	Association of MyProstateScore (MPS) with prostate cancer grade in the radical prostatectomy specimen. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 4.e1-4.e7.	0.8	2
5	Fibroblast Growth Factor Receptor 1 Drives the Metastatic Progression of Prostate Cancer. European Urology Oncology, 2022, 5, 164-175.	2.6	10
6	Biochemical characterization of the interaction between KRAS and Argonaute 2. Biochemistry and Biophysics Reports, 2022, 29, 101191.	0.7	5
7	TERT Promoter Mutations in Keratinizing and Nonkeratinizing Squamous Metaplasia of the Urinary Tract. European Urology Open Science, 2022, 35, 74-78.	0.2	4
8	Direct cellular reprogramming enables development of viral T antigenâ€“driven Merkel cell carcinoma in mice. Journal of Clinical Investigation, 2022, 132, .	3.9	12
9	Targeting SWI/SNF ATPases in enhancer-addicted prostate cancer. Nature, 2022, 601, 434-439.	13.7	110
10	Defining cancer growth beyond the mitotic index. Nature Cell Biology, 2022, 24, 285-287.	4.6	1
11	Metabolism drives macrophage heterogeneity in the tumor microenvironment. Cell Reports, 2022, 39, 110609.	2.9	46
12	CRISPRs in the human genome are differentially expressed between malignant and normalÂadjacent to tumor tissue. Communications Biology, 2022, 5, 338.	2.0	2
13	Urinary MyProstateScore (MPS) to Rule out Clinically-Significant Cancer in Men with Equivocal (PI-RADS 3) Multiparametric MRI: Addressing an Unmet Clinical Need. Urology, 2022, 164, 184-190.	0.5	8
14	Leveraging artificial intelligence to predict ERG gene fusion status in prostate cancer. BMC Cancer, 2022, 22, 494.	1.1	8
15	Adolescent and parent perspectives on genomic sequencing to inform cancer care. Pediatric Blood and Cancer, 2022, 69, .	0.8	2
16	The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma. Nature Communications, 2022, 13, .	5.8	22
17	Germline variants discovered in lymphoma patients undergoing tumor profiling: a case series. Familial Cancer, 2021, 20, 61-65.	0.9	5
18	Immunotherapy for Conjunctival Squamous Cell Carcinoma with Orbital Extension. Ophthalmology, 2021, 128, 801-804.	2.5	10

#	Article	IF	Citations
19	Clinical application of next generation sequencing in lymphoma. Leukemia and Lymphoma, 2021, 62, 868-873.	0.6	3
20	Targeting transcriptional regulation of SARS-CoV-2 entry factorsACE2andTMPRSS2. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	142
21	TSLP-Driven Chromatin Remodeling and Trained Systemic Immunity after Neonatal Respiratory Viral Infection. Journal of Immunology, 2021, 206, 1315-1328.	0.4	12
22	Plasma cells are enriched in localized prostate cancer in Black men and are associated with improved outcomes. Nature Communications, 2021, 12, 935.	5.8	56
23	Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors. JAMA Oncology, 2021, 7, 525-533.	3.4	65
24	A novel ATXN1-DUX4 fusion expands the spectrum of â€˜CIC-rearranged sarcomaâ€™ of the CNS to include non-CIC alterations. Acta Neuropathologica, 2021, 141, 619-622.	3.9	16
25	De novo neuroendocrine transdifferentiation in primary prostate cancerâ€“a phenotype associated with advanced clinico-pathologic features and aggressive outcome. Medical Oncology, 2021, 38, 26.	1.2	18
26	Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma. Cancer Cell, 2021, 39, 361-379.e16.	7.7	189
27	RNA-seq of human T cells after hematopoietic stem cell transplantation identifies Linc00402 as a regulator of T cell alloimmunity. Science Translational Medicine, 2021, 13, .	5.8	6
28	A Randomized Phase II Study of Androgen Deprivation Therapy with or without Palbociclib in RB-positive Metastatic Hormone-Sensitive Prostate Cancer. Clinical Cancer Research, 2021, 27, 3017-3027.	3.2	19
29	Cancer Cell Intrinsic and Immunologic Phenotypes Determine Clinical Outcomes in Basal-like Breast Cancer. Clinical Cancer Research, 2021, 27, 3079-3093.	3.2	8
30	Use of the MyProstateScore Test to Rule Out Clinically Significant Cancer: Validation of a Straightforward Clinical Testing Approach. Journal of Urology, 2021, 205, 732-739.	0.2	21
31	TRIM63 is a sensitive and specific biomarker for MiT family aberration-associated renal cell carcinoma. Modern Pathology, 2021, 34, 1596-1607.	2.9	17
32	Stanniocalcin 1 is a phagocytosis checkpoint driving tumor immune resistance. Cancer Cell, 2021, 39, 480-493.e6.	7.7	71
33	AGO2 promotes tumor progression in KRAS-driven mouse models of nonâ€“small cell lung cancer. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	14
34	CD38 in Advanced Prostate Cancers. European Urology, 2021, 79, 736-746.	0.9	21
35	Single-cell analyses of renal cell cancers reveal insights into tumor microenvironment, cell of origin, and therapy response. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	136
36	Constitutive Hedgehog/GLI2 signaling drives extracutaneous basaloid squamous cell carcinoma development and bone remodeling. Carcinogenesis, 2021, 42, 1100-1109.	1.3	1

#	Article	IF	Citations
37	Association of Urinary MyProstateScore, Age, and Prostate Volume in a Longitudinal Cohort of Healthy Men: Long-term Findings from the Olmsted County Study. European Urology Open Science, 2021, 29, 30-35.	0.2	2
38	A proteogenomic portrait of lung squamous cell carcinoma. Cell, 2021, 184, 4348-4371.e40.	13.5	170
39	Autophagy inhibition by targeting PIKfyve potentiates response to immune checkpoint blockade in prostate cancer. Nature Cancer, 2021, 2, 978-993.	5.7	52
40	Is Universal Next-Generation Sequencing Testing of Patients With Advanced Cancer Ready for Prime Time?â€"Reply. JAMA Oncology, 2021, 7, 1246.	3.4	23
41	Morphological cell profiling of SARS-CoV-2 infection identifies drug repurposing candidates for COVID-19. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	124
42	Comparative Molecular Analysis of Primary Central Nervous System Lymphomas and Matched Vitreoretinal Lymphomas by Vitreous Liquid Biopsy. International Journal of Molecular Sciences, 2021, 22, 9992.	1.8	6
43	Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination. Nature Medicine, 2021, 27, 152-164.	15.2	451
44	Epigenetically defined therapeutic targeting in H3.3G34R/V high-grade gliomas. Science Translational Medicine, 2021, 13, eabf7860.	5.8	18
45	Targeting integrated epigenetic and metabolic pathways in lethal childhood PFA ependymomas. Science Translational Medicine, 2021, 13, eabc0497.	5.8	29
46	HUGO Gene Nomenclature Committee (HGNC) recommendations for the designation of gene fusions. Leukemia, 2021, 35, 3040-3043.	3.3	42
47	G3BP1 inhibits Cul3SPOP to amplify AR signaling and promote prostate cancer. Nature Communications, 2021, 12, 6662.	5.8	17
48	Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate Cancer. European Urology, 2020, 77, 333-341.	0.9	65
49	Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatment. Neoplasia, 2020, 22, 111-119.	2.3	101
50	PAX8 expression and TERT promoter mutations in the nested variant of urothelial carcinoma: a clinicopathologic study with immunohistochemical and molecular correlates. Modern Pathology, 2020, 33, 1165-1171.	2.9	18
51	TERT- beyond the territory: Usage of PCR-based TERT promoter assay in defining urothelial carcinoma in a case of long-standing prostatic adenocarcinoma. Pathology Research and Practice, 2020, 216, 152663.	1.0	1
52	Correlation between cribriform/intraductal prostatic adenocarcinoma and percent Gleason pattern 4 to a 22â€gene genomic classifier. Prostate, 2020, 80, 146-152.	1.2	21
53	Clinicopathological characterisation of renal cell carcinoma in young adults: a contemporary update and review of literature. Histopathology, 2020, 76, 875-887.	1.6	7
54	Multivalent Proteins Rapidly and Reversibly Phase-Separate upon Osmotic Cell Volume Change. Molecular Cell, 2020, 79, 978-990.e5.	4.5	86

#	Article	IF	Citations
55	The Potential of Circular RNAs as Cancer Biomarkers. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 2541-2555.	1.1	19
56	Clinical Sequencing of High-Grade Undifferentiated Sarcomas: A Case Series and Report of an Aggressive Primary Cardiac Tumor With Multiple Oncogenic Drivers. JCO Precision Oncology, 2020, 4, 1061-1069.	1.5	1
57	Impact of the MyProstateScore (MPS) Test on the Clinical Decision to Undergo Prostate Biopsy: Results From a Contemporary Academic Practice. Urology, 2020, 145, 204-210.	0.5	3
58	The DNA methylation landscape of advanced prostate cancer. Nature Genetics, 2020, 52, 778-789.	9.4	198
59	Accelerating precision medicine in metastatic prostate cancer. Nature Cancer, 2020, 1, 1041-1053.	5.7	45
60	Expression of the Androgen Receptor Governs Radiation Resistance in a Subset of Glioblastomas Vulnerable to Antiandrogen Therapy. Molecular Cancer Therapeutics, 2020, 19, 2163-2174.	1.9	17
61	Integrated Metabolic and Epigenomic Reprograming by H3K27M Mutations in Diffuse Intrinsic Pontine Gliomas. Cancer Cell, 2020, 38, 334-349.e9.	7.7	87
62	Cancer SLC43A2 alters T cell methionine metabolism and histone methylation. Nature, 2020, 585, 277-282.	13.7	280
63	Invasive squamous cell carcinomas and precursor lesions on UV-exposed epithelia demonstrate concordant genomic complexity in driver genes. Modern Pathology, 2020, 33, 2280-2294.	2.9	32
64	The role of the histone H3 variant CENPA in prostate cancer. Journal of Biological Chemistry, 2020, 295, 8537-8549.	1.6	43
65	An essential role for Argonaute 2 in EGFR-KRAS signaling in pancreatic cancer development. Nature Communications, 2020, 11, 2817.	5.8	29
66	Is the HERV-K HML-2 Xq21.33, an endogenous retrovirus mutated by gene conversion of chromosome X in a subset of African populations, associated with human breast cancer?. Infectious Agents and Cancer, 2020, 15, 19.	1.2	8
67	Mutations predictive of hyperactive Ras signaling correlate with inferior survival across high-risk pediatric acute leukemia. Translational Pediatrics, 2020, 9, 43-50.	0.5	4
68	Differential modulation of the androgen receptor for prostate cancer therapy depends on the DNA response element. Nucleic Acids Research, 2020, 48, 4741-4755.	6.5	21
69	Diffuse intrinsic pontine glioma-like tumor with EZHIP expression and molecular features of PFA ependymoma. Acta Neuropathologica Communications, 2020, 8, 37.	2.4	20
70	Wnt Signaling Drives Prostate Cancer Bone Metastatic Tropism and Invasion. Translational Oncology, 2020, 13, 100747.	1.7	36
71	Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma. Cell, 2020, 182, 200-225.e35.	13.5	410
72	The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development. Clinical Cancer Research, 2020, 26, 4933-4946.	3.2	53

#	Article	IF	Citations
73	Polypoidal giant cancer cells in metastatic castration-resistant prostate cancer: observations from the Michigan Legacy Tissue Program. Medical Oncology, 2020, 37, 16.	1.2	13
74	Global genomics project unravels cancerâ€™s complexity at unprecedented scale. Nature, 2020, 578, 39-40.	13.7	18
75	Next-generation RNA Sequencingâ€“based Biomarker Characterization of Chromophobe Renal Cell Carcinoma and Related Oncocytic Neoplasms. European Urology, 2020, 78, 63-74.	0.9	57
76	CDK12-Mutated Prostate Cancer: Clinical Outcomes With Standard Therapies and Immune Checkpoint Blockade. JCO Precision Oncology, 2020, 4, 382-392.	1.5	51
77	Case Study: Systematic Detection and Prioritization of Gene Fusions in Cancer by RNA-Seq: A DIY Toolkit. Methods in Molecular Biology, 2020, 2079, 69-79.	0.4	3
78	TTK inhibition radiosensitizes basal-like breast cancer through impaired homologous recombination. Journal of Clinical Investigation, 2020, 130, 958-973.	3.9	53
79	Everolimus improves the efficacy of dasatinib in PDGFRÎ±-driven glioma. Journal of Clinical Investigation, 2020, 130, 5313-5325.	3.9	41
80	Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy. Journal of Clinical Investigation, 2020, 130, 2712-2726.	3.9	112
81	The comprehensive methylation landscape of metastatic castration-resistant prostate cancer (mCRPC) identifies new phenotypic subtypes: Results from the West Coast Prostate Cancer Dream Team (WCDT).. Journal of Clinical Oncology, 2020, 38, 5507-5507.	0.8	0
82	DIPG-59. UPREGULATION OF PRENATAL PONTINE ID1 SIGNALING IN DIPG. Neuro-Oncology, 2020, 22, iii298-iii299.	0.6	0
83	Double-Negative Prostate Cancer Masquerading as a Squamous Cancer of Unknown Primary: A Clinicopathologic and Genomic Sequencing-Based Case Study. JCO Precision Oncology, 2020, 4, 1386-1392.	1.5	4
84	TAMI-42. H3K27M MUTANT GLIOMAS HIJACK A CONSERVED AND CRITICAL METABOLIC PATHWAY USED BY IDH1 MUTANT GLIOMAS TO MAINTAIN THEIR PREFERRED EPIGENETIC STATE. Neuro-Oncology, 2020, 22, ii222-ii222.	0.6	0
85	Role of Aneuploidy in Transcriptional Regulation and Clinical Prognosis in Relapsed and/or Refractory Multiple Myeloma (RRMM). Blood, 2020, 136, 45-46.	0.6	1
86	CTNI-17. CLINICAL EFFICACY AND PREDICTIVE BIOMARKERS OF ONC201 IN H3 K27M-MUTANT DIFFUSE MIDLINE GLIOMA. Neuro-Oncology, 2020, 22, ii45-ii46.	0.6	0
87	Clinical and morphologic review of 60 hereditary renal tumors from 30 hereditary renal cell carcinoma syndrome patients: lessons from a contemporary single institution series. Medical Oncology, 2019, 36, 74.	1.2	15
88	DNA-Dependent Protein Kinase Drives Prostate Cancer Progression through Transcriptional Regulation of the Wnt Signaling Pathway. Clinical Cancer Research, 2019, 25, 5608-5622.	3.2	17
89	Integrative Exome and Transcriptome Analysis of Conjunctival Melanoma and Its Potential Application for Personalized Therapy. JAMA Ophthalmology, 2019, 137, 1444.	1.4	29
90	Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma. Cell, 2019, 179, 964-983.e31.	13.5	430

#	Article	IF	Citations
91	Plasmacytoid urothelial carcinoma: a rapid autopsy case report with unique clinicopathologic and genomic profile. Diagnostic Pathology, 2019, 14, 113.	0.9	8
92	Translating Science to Medicine: When Will the Rubber Meet the Road?. European Urology, 2019, 76, 560-561.	0.9	0
93	Radiotherapy and Immunotherapy Promote Tumoral Lipid Oxidation and Ferroptosis via Synergistic Repression of SLC7A11. Cancer Discovery, 2019, 9, 1673-1685.	7.7	566
94	A clonal expression biomarker associates with lung cancer mortality. Nature Medicine, 2019, 25, 1540-1548.	15.2	75
95	Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer. Nature, 2019, 571, 413-418.	13.7	192
96	Genomic correlates of clinical outcome in advanced prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 11428-11436.	3.3	839
97	CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy. Nature, 2019, 569, 270-274.	13.7	1,528
98	Pediatric craniopharyngioma in association with familial adenomatous polyposis. Familial Cancer, 2019, 18, 327-330.	0.9	6
99	Functional and Mechanistic Interrogation of BET Bromodomain Degraders for the Treatment of Metastatic Castration-resistant Prostate Cancer. Clinical Cancer Research, 2019, 25, 4038-4048.	3.2	26
100	Dynamic Recruitment of Single RNAs to Processing Bodies Depends on RNA Functionality. Molecular Cell, 2019, 74, 521-533.e6.	4.5	100
101	Activation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate Cancer. Cancer Research, 2019, 79, 2580-2592.	0.4	85
102	Characterizing the Therapeutic Potential of a Potent BET Degrader in Merkel Cell Carcinoma. Neoplasia, 2019, 21, 322-330.	2.3	10
103	The Landscape of Circular RNA in Cancer. Cell, 2019, 176, 869-881.e13.	13.5	1,095
104	Polycomb group proteins EZH2 and EED directly regulate androgen receptor in advanced prostate cancer. International Journal of Cancer, 2019, 145, 415-426.	2.3	51
105	Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a de novo low AR-Active Subclass in Treatment NaÃ¯ve Primary Prostate Cancer. Clinical Cancer Research, 2019, 25, 6721-6730.	3.2	74
106	The Role of Non-coding RNAs in Oncology. Cell, 2019, 179, 1033-1055.	13.5	952
107	The utility of upper urinary tract urine cytology before and after application of the Paris system. Diagnostic Cytopathology, 2019, 47, 421-427.	0.5	19
108	Nextâ€generation sequencing in precision oncology: Patient understanding and expectations. Cancer Medicine, 2019, 8, 227-237.	1.3	36

#	Article	IF	Citations
109	Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency. European Urology, 2019, 75, 184-192.	0.9	69
110	Clinical utility and concordance of upper urinary tract cytology and biopsy in predicting clinicopathological features of upper urinary tract urothelial carcinoma. Human Pathology, 2019, 86, 76-84.	1.1	16
111	Metastatic castration resistant prostate cancer with squamous cell, small cell, and sarcomatoid elementsâ€"a clinicopathologic and genomic sequencing-based discussion. Medical Oncology, 2019, 36, 27.	1.2	8
112	Aneuploidy Is Associated with Inferior Survival in Relapsed Refractory Multiple Myeloma Patients. Blood, 2019, 134, 4360-4360.	0.6	3
113	SUN-003 Targeting Androgen Receptor-CXCR7-MARK Signaling Axis in CRPC. Journal of the Endocrine Society, 2019, 3, .	0.1	0
114	Integrated Genomic-Transcriptomic Study Highlights Accumulation of Genetic Variants and Activation of Inflammatory Pathways. Blood, 2019, 134, 4212-4212.	0.6	0
115	MechRNA: prediction of lncRNA mechanisms from RNAâ€"RNA and RNAâ€"protein interactions. Bioinformatics, 2018, 34, 3101-3110.	1.8	48
116	Multigene Profiling of CTCs in mCRPC Identifies a Clinically Relevant Prognostic Signature. Molecular Cancer Research, 2018, 16, 643-654.	1.5	33
117	Detailed pathologic analysis on the co-occurrence of non-seminomatous germ cell tumor subtypes in matched orchiectomy and retroperitoneal lymph node dissections. Medical Oncology, 2018, 35, 21.	1.2	3
118	Cancer transcriptome profiling at the juncture of clinical translation. Nature Reviews Genetics, 2018, 19, 93-109.	7.7	202
119	The CARMA3â€"Bcl10â€"MALT1 Signalosome Drives NFÎºB Activation and Promotes Aggressiveness in Angiotensin II Receptorâ€"Positive Breast Cancer. Cancer Research, 2018, 78, 1225-1240.	0.4	65
120	Precision oncology in the age of integrative genomics. Nature Biotechnology, 2018, 36, 46-60.	9.4	104
121	Circumscribed/non-diffuse histology confers a better prognosis in H3K27M-mutant gliomas. Acta Neuropathologica, 2018, 135, 299-301.	3.9	51
122	BRAF activating mutations involving the Î²3-Î±C loop in V600E-negative anaplastic pleomorphic xanthoastrocytoma. Acta Neuropathologica Communications, 2018, 6, 24.	2.4	16
123	The long tail of oncogenic drivers in prostate cancer. Nature Genetics, 2018, 50, 645-651.	9.4	601
124	Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC). Clinical Cancer Research, 2018, 24, 3149-3162.	3.2	111
125	Comprehensive Evaluation of Programmed Death-Ligand 1 Expression in Primary and Metastatic Prostate Cancer. American Journal of Pathology, 2018, 188, 1478-1485.	1.9	119
126	The utility of SDHB and FH immunohistochemistry in patients evaluated for hereditary paraganglioma-pheochromocytoma syndromes. Human Pathology, 2018, 71, 47-54.	1.1	39

#	Article	IF	Citations
127	miR-34a Regulates Expression of the Stathmin-1 Oncoprotein and Prostate Cancer Progression. Molecular Cancer Research, 2018, 16, 1125-1137.	1.5	51
128	Detection of 6 TFEB-amplified renal cell carcinomas and 25 renal cell carcinomas with MITF translocations: systematic morphologic analysis of 85 cases evaluated by clinical TFE3 and TFEB FISH assays. Modern Pathology, 2018, 31, 179-197.	2.9	73
129	Physician Experiences and Understanding of Genomic Sequencing in Oncology. Journal of Genetic Counseling, 2018, 27, 187-196.	0.9	24
130	Comprehensive Mutation and Copy Number Profiling in Archived Circulating Breast Cancer Tumor Cells Documents Heterogeneous Resistance Mechanisms. Cancer Research, 2018, 78, 1110-1122.	0.4	85
131	Development of the CNS TAP tool for the selection of precision medicine therapies in neuro-oncology. Journal of Neuro-Oncology, 2018, 137, 155-169.	1.4	15
132	Targeting the MYCNâ€“PARPâ€“DNA Damage Response Pathway in Neuroendocrine Prostate Cancer. Clinical Cancer Research, 2018, 24, 696-707.	3.2	80
133	Clinical validation of the Tempus xO assay. Oncotarget, 2018, 9, 25826-25832.	0.8	43
134	VSTM2A Overexpression Is a Sensitive and Specific Biomarker for Mucinous Tubular and Spindle Cell Carcinoma (MTSCC) of the Kidney. American Journal of Surgical Pathology, 2018, 42, 1571-1584.	2.1	34
135	Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. Journal of Clinical Oncology, 2018, 36, 991-999.	0.8	169
136	Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer. Journal of Clinical Investigation, 2018, 128, 4441-4453.	3.9	155
137	Clinically Integrated Sequencing Alters Therapy in Children and Young Adults With High-Risk Glial Brain Tumors. JCO Precision Oncology, 2018, 2, 1-34.	1.5	10
138	Association of ERG/PTEN status with biochemical recurrence after radical prostatectomy for clinically localized prostate cancer. Medical Oncology, 2018, 35, 152.	1.2	13
139	MiPanda: A Resource for Analyzing and Visualizing Next-Generation Sequencing Transcriptomics Data. Neoplasia, 2018, 20, 1144-1149.	2.3	20
140	Genomic Landscape and Clinical Features of Triple-Negative Myelofibrosis. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S268.	0.2	1
141	Analysis of the androgen receptorâ€“regulated lncRNA landscape identifies a role for ARLNC1 in prostate cancer progression. Nature Genetics, 2018, 50, 814-824.	9.4	196
142	Genetic diversity of NDUFV1-dependent mitochondrial complex I deficiency. European Journal of Human Genetics, 2018, 26, 1582-1587.	1.4	15
143	Somatic Bi-allelic Loss of TSC Genes in Eosinophilic Solid and Cystic Renal Cell Carcinoma. European Urology, 2018, 74, 483-486.	0.9	86
144	miR-34a directly targets tRNA _i ^{Met} precursors and affects cellular proliferation, cell cycle, and apoptosis. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 7392-7397.	3.3	44

#	Article	IF	Citations
145	Frequent PD-L1 Protein Expression and Molecular Correlates in Urinary Bladder Squamous Cell Carcinoma. European Urology, 2018, 74, 529-531.	0.9	17
146	Competing for enhancers: PVT1 fine-tunes MYC expression. Cell Research, 2018, 28, 785-786.	5.7	15
147	Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. Cell, 2018, 174, 758-769.e9.	13.5	459
148	Medulloblastoma therapy generates risk of a poorly-prognostic H3 wild-type subgroup of diffuse intrinsic pontine glioma: a report from the International DIPG Registry. Acta Neuropathologica Communications, 2018, 6, 67.	2.4	12
149	Epigenetic Reprogramming with Antisense Oligonucleotides Enhances the Effectiveness of Androgen Receptor Inhibition in Castration-Resistant Prostate Cancer. Cancer Research, 2018, 78, 5731-5740.	0.4	40
150	Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer. Cell, 2018, 173, 1770-1782.e14.	13.5	400
151	A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors. Nature Genetics, 2018, 50, 979-989.	9.4	168
152	Transcriptomic heterogeneity in multifocal prostate cancer. JCI Insight, 2018, 3, .	2.3	71
153	Host expression of PD-L1 determines efficacy of PD-L1 pathway blockadeâ€“mediated tumor regression. Journal of Clinical Investigation, 2018, 128, 805-815.	3.9	423
154	Integrative Next Generation Sequencing of Myeloproliferative Neoplasms and Correlation of Genetic Variations to Disease Severity. Blood, 2018, 132, 4324-4324.	0.6	1
155	Dynamic changes during the treatment of pancreatic cancer. Oncotarget, 2018, 9, 14764-14790.	0.8	21
156	Programmed Death-ligand 1 Expression in Upper Tract Urothelial Carcinoma. European Urology Focus, 2017, 3, 502-509.	1.6	25
157	Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy. JAMA Oncology, 2017, 3, 1663.	3.4	219
158	Immunohistochemical Characterization of Fumarate Hydratase (FH) and Succinate Dehydrogenase (SDH) in Cutaneous Leiomyomas for Detection of Familial Cancer Syndromes. American Journal of Surgical Pathology, 2017, 41, 801-809.	2.1	33
159	Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition. Cancer Discovery, 2017, 7, 1006-1017.	7.7	341
160	Age and Gender Associations of Virus Positivity in Merkel Cell Carcinoma Characterized Using a Novel RNA In Situ Hybridization Assay. Clinical Cancer Research, 2017, 23, 5622-5630.	3.2	31
161	Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer. Cancer Cell, 2017, 31, 532-548.e7.	7.7	85
162	Clinical characteristics and whole exome/transcriptome sequencing of coexisting chronic myeloid leukemia and myelofibrosis. American Journal of Hematology, 2017, 92, 555-561.	2.0	12

#	Article	IF	Citations
163	Preclinical Evaluation of ¹¹C-Sarcosine as a Substrate of Proton-Coupled Amino Acid Transporters and First Human Application in Prostate Cancer. Journal of Nuclear Medicine, 2017, 58, 1216-1223.	2.8	15
164	SPOP Mutation Drives Prostate Tumorigenesis InÂVivo through Coordinate Regulation of PI3K/mTOR and AR Signaling. Cancer Cell, 2017, 31, 436-451.	7.7	152
165	Rare Presentation of Metastatic Cystic Trophoblastic Tumor in aÂPatient Without Prior Chemotherapy. Urology Case Reports, 2017, 13, 154-157.	0.1	4
166	Gene Copy Number Estimation from Targeted Next-Generation Sequencing of Prostate Cancer Biopsies: Analytic Validation and Clinical Qualification. Clinical Cancer Research, 2017, 23, 6070-6077.	3.2	30
167	Integrative clinical genomics of metastatic cancer. Nature, 2017, 548, 297-303.	13.7	685
168	Blood-brain barrierâ€“adapted precision medicine therapy for pediatric brain tumors. Translational Research, 2017, 188, 27.e1-27.e14.	2.2	12
169	Comprehensive Molecular Profiling of Olfactory Neuroblastoma Identifies Potentially Targetable FGFR3 Amplifications. Molecular Cancer Research, 2017, 15, 1551-1557.	1.5	37
170	Oncogenic Role of THOR, a Conserved Cancer/Testis Long Non-coding RNA. Cell, 2017, 171, 1559-1572.e20.	13.5	200
171	Rapid molecular assays to study human centromere genomics. Genome Research, 2017, 27, 2040-2049.	2.4	24
172	Precision medicine in pediatric oncology: Lessons learned and next steps. Pediatric Blood and Cancer, 2017, 64, e26288.	0.8	71
173	Expression and Role of PAICS, a De Novo Purine Biosynthetic Gene in Prostate Cancer. Prostate, 2017, 77, 10-21.	1.2	37
174	The Emergence of Precision Urologic Oncology: A Collaborative Review on Biomarker-driven Therapeutics. European Urology, 2017, 71, 237-246.	0.9	62
175	Development of a RNA-Seq Based Prognostic Signature in Lung Adenocarcinoma. Journal of the National Cancer Institute, 2017, 109, djw200.	3.0	150
176	Genome-Wide STAT3 Binding Analysis after Histone Deacetylase Inhibition Reveals Novel Target Genes in Dendritic Cells. Journal of Innate Immunity, 2017, 9, 126-144.	1.8	8
177	TACO produces robust multisample transcriptome assemblies from RNA-seq. Nature Methods, 2017, 14, 68-70.	9.0	157
178	Rapid, ultra low coverage copy number profiling of cell-free DNA as a precision oncology screening strategy. Oncotarget, 2017, 8, 89848-89866.	0.8	45
179	Next generation sequencing of extraskeletal myxoid chondrosarcoma. Oncotarget, 2017, 8, 21770-21777.	0.8	20
180	Two-pass alignment improves novel splice junction quantification. Bioinformatics, 2016, 32, 43-49.	1.8	46

#	Article	IF	Citations
181	PDCT-03. CLINICALLY INTEGRATED SEQUENCING IN THE MANAGEMENT OF CHILDREN WITH HIGH-RISK BRAIN TUMORS. Neuro-Oncology, 2016, 18, vi145-vi146.	0.6	0
182	Heat Shock Protein Beta-1 Modifies Anterior to Posterior Purkinje Cell Vulnerability in a Mouse Model of Niemann-Pick Type C Disease. PLoS Genetics, 2016, 12, e1006042.	1.5	18
183	Incorporating genetic counseling into clinical care for children and adolescents with cancer. Future Oncology, 2016, 12, 883-886.	1.1	7
184	Concurrent nuclear ERG and MYC protein overexpression defines a subset of locally advanced prostate cancer: Potential opportunities for synergistic targeted therapeutics. Prostate, 2016, 76, 845-853.	1.2	9
185	Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. New England Journal of Medicine, 2016, 375, 443-453.	13.9	1,205
186	Inflammation-Induced Oxidative Stress Mediates Gene Fusion Formation in Prostate Cancer. Cell Reports, 2016, 17, 2620-2631.	2.9	68
187	Identification and Validation of PCAT14 as Prognostic Biomarker in Prostate Cancer. Neoplasia, 2016, 18, 489-499.	2.3	55
188	Comparative analysis of circulating tumor DNA stability In K3EDTA, Streck, and CellSave blood collection tubes. Clinical Biochemistry, 2016, 49, 1354-1360.	0.8	175
189	Clinical Sequencing Exploratory Research Consortium: Accelerating Evidence-Based Practice of Genomic Medicine. American Journal of Human Genetics, 2016, 98, 1051-1066.	2.6	137
190	Biallelic Alteration and Dysregulation of the Hippo Pathway in Mucinous Tubular and Spindle Cell Carcinoma of the Kidney. Cancer Discovery, 2016, 6, 1258-1266.	7.7	66
191	Prostatic Adenocarcinoma With Hormone Exposure Related Changes in a Patient With Hepatic Cirrhosis â€“ Value of Autopsy in a Case Report. Urology Case Reports, 2016, 9, 37-40.	0.1	0
192	Role of BET proteins in castration-resistant prostate cancer. Drug Discovery Today: Technologies, 2016, 19, 29-38.	4.0	15
193	Translating cancer genomes and transcriptomes for precision oncology. Ca-A Cancer Journal for Clinicians, 2016, 66, 75-88.	157.7	133
194	Lowered H3K27me3 and DNA hypomethylation define poorly prognostic pediatric posterior fossa ependymomas. Science Translational Medicine, 2016, 8, 366ra161.	5.8	144
195	The lncRNA landscape of breast cancer reveals a role for DSCAM-AS1 in breast cancer progression. Nature Communications, 2016, 7, 12791.	5.8	196
196	Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment. European Urology, 2016, 70, 45-53.	0.9	304
197	The Potential of MicroRNAs as Prostate Cancer Biomarkers. European Urology, 2016, 70, 312-322.	0.9	243
198	Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate Cancer. Neoplasia, 2016, 18, 1-9.	2.3	25

#	Article	IF	Citations
199	BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer. Molecular Cancer Research, 2016, 14, 324-331.	1.5	137
200	KRAS Engages AGO2 to Enhance Cellular Transformation. Cell Reports, 2016, 14, 1448-1461.	2.9	41
201	Prognostic Value of Percent Gleason Grade 4 at Prostate Biopsy in Predicting Prostatectomy Pathology and Recurrence. Journal of Urology, 2016, 196, 405-411.	0.2	89
202	Expression of PDL1 (B7-H1) Before and After Neoadjuvant Chemotherapy in Urothelial Carcinoma. European Urology Focus, 2016, 1, 265-268.	1.6	45
203	Overexpression of the Long Non-coding RNA SChLAP1 Independently Predicts Lethal Prostate Cancer. European Urology, 2016, 70, 549-552.	0.9	121
204	De novodominantASXL3mutations alter H2A deubiquitination and transcription in Bainbridgeâ€“Ropers syndrome. Human Molecular Genetics, 2016, 25, 597-608.	1.4	56
205	Germline Findings in Tumor-Only Sequencing: Points to Consider for Clinicians and Laboratories: Table 1.. Journal of the National Cancer Institute, 2016, 108, djv351.	3.0	86
206	ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients. Clinical Cancer Research, 2016, 22, 993-999.	3.2	152
207	Cancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction. Nature Immunology, 2016, 17, 95-103.	7.0	310
208	The bright side of dark matter: lncRNAs in cancer. Journal of Clinical Investigation, 2016, 126, 2775-2782.	3.9	353
209	Non-coding RNA LINC00857 is predictive of poor patient survival and promotes tumor progression via cell cycle regulation in lung cancer. Oncotarget, 2016, 7, 11487-11499.	0.8	51
210	A comparative assessment of clinical whole exome and transcriptome profiling across sequencing centers: implications for precision cancer medicine. Oncotarget, 2016, 7, 52888-52899.	0.8	18
211	A subset of solitary fibrous tumors express nuclear PAX8 and PAX2: a potential diagnostic pitfall. Histology and Histopathology, 2016, 31, 223-30.	0.5	6
212	Molecular profiling of ETS and nonâ€ETS aberrations in prostate cancer patients from northern India. Prostate, 2015, 75, 1051-1062.	1.2	17
213	Landscape of gene fusions in epithelial cancers: seq and ye shall find. Genome Medicine, 2015, 7, 129.	3.6	127
214	Role and regulation of coordinately expressedde novopurine biosynthetic enzymesPPATandPAICSin lung cancer. Oncotarget, 2015, 6, 23445-23461.	0.8	80
215	Integrative Clinical Genomics of Advanced Prostate Cancer. Cell, 2015, 161, 1215-1228.	13.5	2,660
216	The landscape of antisense gene expression in human cancers. Genome Research, 2015, 25, 1068-1079.	2.4	150

#	Article	IF	Citations
217	The landscape of long noncoding RNAs in the human transcriptome. Nature Genetics, 2015, 47, 199-208.	9.4	2,410
218	rSeqNP: a non-parametric approach for detecting differential expression and splicing from RNA-Seq data. Bioinformatics, 2015, 31, 2222-2224.	1.8	13
219	Development and Validation of a Scalable Next-Generation Sequencing System for Assessing Relevant Somatic Variants in Solid Tumors. Neoplasia, 2015, 17, 385-399.	2.3	212
220	Impact of tertiary Gleason pattern 5 on prostate cancer aggressiveness: Lessons from a contemporary single institution radical prostatectomy series. Asian Journal of Urology, 2015, 2, 53-58.	0.5	12
221	Galanin modulates the neural niche to favour perineural invasion in head and neck cancer. Nature Communications, 2015, 6, 6885.	5.8	85
222	Molecular and Immunohistochemical Characterization Reveals Novel BRAF Mutations in Metanephric Adenoma. American Journal of Surgical Pathology, 2015, 39, 549-557.	2.1	43
223	Targeting the MLL complex in castration-resistant prostate cancer. Nature Medicine, 2015, 21, 344-352.	15.2	165
224	aBETting therapeutic resistance by Wnt signaling. Cell Research, 2015, 25, 1187-1188.	5.7	9
225	DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. New England Journal of Medicine, 2015, 373, 1697-1708.	13.9	1,796
226	Long Noncoding RNAs in Cancer: From Function to Translation. Trends in Cancer, 2015, 1, 93-109.	3.8	218
227	The use of exome capture RNA-seq for highly degraded RNA with application to clinical cancer sequencing. Genome Research, 2015, 25, 1372-1381.	2.4	139
228	Urothelial Cancer With Occult Bone Marrow Metastases and Isolated Thrombocytopenia. Urology Case Reports, 2015, 3, 98-100.	0.1	2
229	Clinicopathologic characteristics of anterior prostate cancer (APC), including correlation with previous biopsy pathology. Medical Oncology, 2015, 32, 249.	1.2	10
230	Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth. JAMA - Journal of the American Medical Association, 2015, 314, 913.	3.8	333
231	The Distinctive Mutational Spectra of Polyomavirus-Negative Merkel Cell Carcinoma. Cancer Research, 2015, 75, 3720-3727.	0.4	276
232	Reply to Carsten Stephan, Henning Cammann, and Klaus Jung's Letter to the Editor re: Scott A. Tomlins, John R. Day, Robert J. Lonigro, et al. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.04.039. European Urology, 2015, 68, e108.	0.9	12
233	Molecular profiling of ETS gene rearrangements in patients with prostate cancer registered in REDEEM clinical trial1Share senior authorship.. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 108.e5-108.e13.	0.8	3
234	Coactivator SRC-2â€“dependent metabolic reprogramming mediates prostate cancer survival and metastasis. Journal of Clinical Investigation, 2015, 125, 1174-1188.	3.9	78

#	Article	IF	Citations
235	Genome-Wide Binding Studies of Acetyl-STAT3 Demonstrates a Novel Regulatory Pathway in Dendritic Cells. Blood, 2015, 126, 647-647.	0.6	0
236	The lncRNAs PCGEM1 and PRNCR1 are not implicated in castration resistant prostate cancer. Oncotarget, 2014, 5, 1434-1438.	0.8	106
237	BETting on a new prostate cancer treatment. Cell Cycle, 2014, 13, 2015-2016.	1.3	3
238	Prostate cancer cellâ€“stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases. Science Translational Medicine, 2014, 6, 252ra122.	5.8	86
239	Consensus statement with recommendations on active surveillance inclusion criteria and definition of progression in men with localized prostate cancer: the critical role of the pathologist. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2014, 465, 623-628.	1.4	41
240	A Novel RNA In Situ Hybridization Assay for the Long Noncoding RNA SChLAP1 Predicts Poor Clinical Outcome After Radical Prostatectomy in Clinically Localized Prostate Cancer. Neoplasia, 2014, 16, 1121-1127.	2.3	81
241	The Long Non-Coding RNA PCAT-1 Promotes Prostate Cancer Cell Proliferation through cMyc. Neoplasia, 2014, 16, 900-908.	2.3	216
242	The Critical Role of the Pathologist in Determining Eligibility for Active Surveillance as a Management Option in Patients With Prostate Cancer: Consensus Statement With Recommendations Supported by the College of American Pathologists, International Society of Urological Pathology, Association of Directors of Anatomic and Surgical Pathology, the New Zealand Society of Pathologists, and the Prostate Cancer Foundation. Archives of Pathology and Laboratory Medicine, 2014, 138, 1387-1405.	1.2	117
243	Activating mutations of the oncogene EZH2 in cutaneous melanoma revealed by next generation sequencing. Human Pathology: Case Reports, 2014, 1, 21-28.	0.2	10
244	Frequent discordance betweenERGgene rearrangement and ERG protein expression in a rapid autopsy cohort of patients with lethal, metastatic, castration-resistant prostate cancer. Prostate, 2014, 74, 1199-1208.	1.2	33
245	Transcriptome meta-analysis of lung cancer reveals recurrent aberrations in NRG1 and Hippo pathway genes. Nature Communications, 2014, 5, 5893.	5.8	121
246	RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1. Lancet Oncology, The, 2014, 15, 1469-1480.	5.1	226
247	RNA-Seq Accurately Identifies Cancer Biomarker Signatures to Distinguish Tissue of Origin. Neoplasia, 2014, 16, 918-927.	2.3	37
248	Estrogen receptor mutations and their role in breast cancer progression. Breast Cancer Research, 2014, 16, 494.	2.2	83
249	Immunohistochemical Staining Characteristics of Nephrogenic Adenoma Using the PIN-4 Cocktail (p63,) Tj ETQq1 1 0.784314 rgBT /Ov	2.1	31
250	HOXB13 G84Eâ€“related Familial Prostate Cancers. American Journal of Surgical Pathology, 2014, 38, 615-626.	2.1	41
251	Molecular Pathways: Targeting ETS Gene Fusions in Cancer. Clinical Cancer Research, 2014, 20, 4442-4448.	3.2	54
252	Clinical Tumor Sequencing: An Incidental Casualty of the American College of Medical Genetics and Genomics Recommendations for Reporting of Incidental Findings. Journal of Clinical Oncology, 2014, 32, 2203-2205.	0.8	36

#	Article	IF	Citations
253	Antibodyâ€independent targeted quantification of TMPRSS2â€ERG fusion protein products in prostate cancer. Molecular Oncology, 2014, 8, 1169-1180.	2.1	24
254	Primary Urethral Clear-Cell Adenocarcinoma. American Journal of Pathology, 2014, 184, 584-591.	1.9	46
255	Papillary renal cell carcinoma revisited: a comprehensive histomorphologic study with outcome correlations. Human Pathology, 2014, 45, 1139-1146.	1.1	25
256	Evaluation of tissue PCA3 expression in prostate cancer by RNA in situ hybridizationâ€"a correlative study with urine PCA3 and TMPRSS2-ERG. Modern Pathology, 2014, 27, 609-620.	2.9	37
257	PCAT-1, a Long Noncoding RNA, Regulates BRCA2 and Controls Homologous Recombination in Cancer. Cancer Research, 2014, 74, 1651-1660.	0.4	237
258	Metabolomic Profiling Identifies Biochemical Pathways Associated with Castration-Resistant Prostate Cancer. Journal of Proteome Research, 2014, 13, 1088-1100.	1.8	49
259	The central role of EED in the orchestration of polycomb group complexes. Nature Communications, 2014, 5, 3127.	5.8	130
260	HRAS mutations are frequent in inverted urothelial neoplasms. Human Pathology, 2014, 45, 1957-1965.	1.1	39
261	Prostate cancer with Paneth cellâ€"like neuroendocrine differentiation has recognizable histomorphology and harbors AURKA gene amplification. Human Pathology, 2014, 45, 2136-2143.	1.1	28
262	TRIP13 promotes error-prone nonhomologous end joining and induces chemoresistance in head and neck cancer. Nature Communications, 2014, 5, 4527.	5.8	129
263	Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature, 2014, 510, 278-282.	13.7	811
264	The lncRNA PCAT29 Inhibits Oncogenic Phenotypes in Prostate Cancer. Molecular Cancer Research, 2014, 12, 1081-1087.	1.5	119
265	BETs abet Tam-R in ER-positive breast cancer. Cell Research, 2014, 24, 899-900.	5.7	11
266	KRAS Protein Stability Is Regulated through SMURF2: UBCH5 Complex-Mediated Î²-TrCP1 Degradation. Neoplasia, 2014, 16, 115-W5.	2.3	74
267	RNA Identity Crisis: Hepatitis B Walks the LINE. Cancer Cell, 2014, 25, 259-260.	7.7	6
268	The miR-124-Prolyl Hydroxylase P4HA1-MMP1 axis plays a critical role in prostate cancer progression. Oncotarget, 2014, 5, 6654-6669.	0.8	82
269	HR-MAS NMR Tissue Metabolomic Signatures Cross-validated by Mass Spectrometry Distinguish Bladder Cancer from Benign Disease. Journal of Proteome Research, 2013, 12, 3519-3528.	1.8	54
270	Targeted Radiosensitization of ETS Fusion-Positive Prostate Cancer through PARP1 Inhibition. Neoplasia, 2013, 15, 1207-IN36.	2.3	49

#	Article	IF	Citations
271	The Role of Sarcosine Metabolism in Prostate Cancer Progression. Neoplasia, 2013, 15, 491-IN13.	2.3	134
272	Comprehensive Analysis of ETS Family Members in Melanoma by Fluorescence In Situ Hybridization Reveals Recurrent ETV1 Amplification. Translational Oncology, 2013, 6, 405-412.	1.7	13
273	The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex. Nature Genetics, 2013, 45, 1392-1398.	9.4	601
274	Identification of Targetable FGFR Gene Fusions in Diverse Cancers. Cancer Discovery, 2013, 3, 636-647.	7.7	614
275	Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing. Nature Genetics, 2013, 45, 180-185.	9.4	662
276	Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nature Genetics, 2013, 45, 1446-1451.	9.4	925
277	Advancing Precision Medicine for Prostate Cancer Through Genomics. Journal of Clinical Oncology, 2013, 31, 1866-1873.	0.8	84
278	Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 566-571.	0.8	181
279	MicroRNA expression patterns in indeterminate inflammatory bowel disease. Modern Pathology, 2013, 26, 148-154.	2.9	48
280	Characterization of the EZH2-MMSET Histone Methyltransferase Regulatory Axis in Cancer. Molecular Cell, 2013, 49, 80-93.	4.5	130
281	Noncoding RNAs and Cancer. Cell, 2013, 153, 9-10.	13.5	40
282	Novel dual-color immunohistochemical methods for detecting ERGâ€“PTEN and ERGâ€“SPINK1 status in prostate carcinoma. Modern Pathology, 2013, 26, 835-848.	2.9	47
283	HIV infection reveals widespread expansion of novel centromeric human endogenous retroviruses. Genome Research, 2013, 23, 1505-1513.	2.4	72
284	Next-Generation Sequencing Identifies the Danforth's Short Tail Mouse Mutation as a Retrotransposon Insertion Affecting Ptf1a Expression. PLoS Genetics, 2013, 9, e1003205.	1.5	23
285	Usefulness of a Monoclonal ERG/FLI1 Antibody for Immunohistochemical Discrimination of Ewing Family Tumors. American Journal of Clinical Pathology, 2013, 139, 771-779.	0.4	34
286	Outlier Kinase Expression by RNA Sequencing as Targets for Precision Therapy. Cancer Discovery, 2013, 3, 280-293.	7.7	40
287	Recurrent reciprocal RNA chimera involving YPEL5 and PPP1CB in chronic lymphocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 3035-3040.	3.3	44
288	Allogeneic T cell responses are regulated by a specific miRNA-mRNA network. Journal of Clinical Investigation, 2013, 123, 4739-4754.	3.9	36

#	Article	IF	Citations
289	Circulating microRNA Profiling Identifies a Subset of Metastatic Prostate Cancer Patients with Evidence of Cancer-Associated Hypoxia. PLoS ONE, 2013, 8, e69239.	1.1	147
290	The Histone Methyltransferase Ezh2 Is a Crucial Epigenetic Regulator Of Allogeneic T Cell Responses and Graft-Versus-Host Disease In Mice. Blood, 2013, 122, 137-137.	0.6	0
291	Correlation of UrineTMPRSS2:ERGandPCA3to ERG+ and Total Prostate Cancer Burden. American Journal of Clinical Pathology, 2012, 138, 685-696.	0.4	72
292	Antibody-Based Detection of ERG Rearrangements in Prostate Core Biopsies, Including Diagnostically Challenging Cases: ERG Staining in Prostate Core Biopsies. Archives of Pathology and Laboratory Medicine, 2012, 136, 935-946.	1.2	88
293	Common Structural and Epigenetic Changes in the Genome of Castration-Resistant Prostate Cancer. Cancer Research, 2012, 72, 616-625.	0.4	111
294	Next Generation Sequencing of Prostate Cancer from a Patient Identifies a Deficiency of Methylthioadenosine Phosphorylase, an Exploitable Tumor Target. Molecular Cancer Therapeutics, 2012, 11, 775-783.	1.9	34
295	SLC45A3-ELK4 Chimera in Prostate Cancer: Spotlight on cis-Splicing. Cancer Discovery, 2012, 2, 582-585.	7.7	40
296	Insights into Chinese prostate cancer with RNA-seq. Cell Research, 2012, 22, 786-788.	5.7	4
297	A Dual Role for Receptor-interacting Protein Kinase 2 (RIP2) Kinase Activity in Nucleotide-binding Oligomerization Domain 2 (NOD2)-dependent Autophagy. Journal of Biological Chemistry, 2012, 287, 25565-25576.	1.6	73
298	Identification of functionally active, low frequency copy number variants at 15q21.3 and 12q21.31 associated with prostate cancer risk. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 6686-6691.	3.3	49
299	The Enzymatic Activity of Apoptosis-inducing Factor Supports Energy Metabolism Benefiting the Growth and Invasiveness of Advanced Prostate Cancer Cells. Journal of Biological Chemistry, 2012, 287, 43862-43875.	1.6	19
300	Inhibition of histone methylation arrests ongoing graft-versus-host disease in mice by selectively inducing apoptosis of alloreactive effector T cells. Blood, 2012, 119, 1274-1282.	0.6	70
301	Androgen receptor activation results in metabolite signatures of an aggressive prostate cancer phenotype: an NMR-based metabonomics study. Metabolomics, 2012, 8, 1026-1036.	1.4	14
302	Role of Transcriptional Corepressor CtBP1 in Prostate Cancer Progression. Neoplasia, 2012, 14, 905-IN8.	2.3	59
303	Gene Fusions Associated with Recurrent Amplicons Represent a Class of Passenger Aberrations in Breast Cancer. Neoplasia, 2012, 14, 702-IN13.	2.3	60
304	PARP-1 Inhibition as a Targeted Strategy to Treat Ewing's Sarcoma. Cancer Research, 2012, 72, 1608-1613.	0.4	246
305	Dual Roles of PARP-1 Promote Cancer Growth and Progression. Cancer Discovery, 2012, 2, 1134-1149.	7.7	354
306	Systematic, evidence-based discovery of biomarkers at the NCI. Clinical and Experimental Metastasis, 2012, 29, 645-652.	1.7	22

#	Article	IF	Citations
307	Pathway-directed weighted testing procedures for the integrative analysis of gene expression and metabolomic data. Genomics, 2012, 99, 265-274.	1.3	10
308	Beyond PSA: The Next Generation of Prostate Cancer Biomarkers. Science Translational Medicine, 2012, 4, 127rv3.	5.8	378
309	The mutational landscape of lethal castration-resistant prostate cancer. Nature, 2012, 487, 239-243.	13.7	2,128
310	Delineating metabolic signatures of head and neck squamous cell carcinoma: Phospholipase A2, a potential therapeutic target. International Journal of Biochemistry and Cell Biology, 2012, 44, 1852-1861.	1.2	87
311	Analysis of the Tau-Associated Proteome Reveals That Exchange of Hsp70 for Hsp90 Is Involved in Tau Degradation. ACS Chemical Biology, 2012, 7, 1677-1686.	1.6	72
312	Expressed Pseudogenes in the Transcriptional Landscape of Human Cancers. Cell, 2012, 149, 1622-1634.	13.5	250
313	Variable Reference Alignment: An Improved Peak Alignment Protocol for NMR Spectral Data with Large Intersample Variation. Analytical Chemistry, 2012, 84, 5372-5379.	3.2	26
314	Genetic and epigenetic loss of microRNA-31 leads to feed-forward expression of EZH2 in melanoma. Oncotarget, 2012, 3, 1011-1025.	0.8	126
315	Histone Methyltransferase Ezh2 Controls T-Cell Immunity by Regulating Bioenergetic Metabolism. Blood, 2012, 120, 953-953.	0.6	0
316	Common Gene Rearrangements in Prostate Cancer. Journal of Clinical Oncology, 2011, 29, 3659-3668.	0.8	268
317	Discovery of non-ETS gene fusions in human prostate cancer using next-generation RNA sequencing. Genome Research, 2011, 21, 56-67.	2.4	179
318	Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer. Nature Medicine, 2011, 17, 1646-1651.	15.2	301
319	Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumors. Genome Research, 2011, 21, 47-55.	2.4	148
320	Detection of Somatic Copy Number Alterations in Cancer Using Targeted Exome Capture Sequencing. Neoplasia, 2011, 13, 1019-IN21.	2.3	74
321	Therapeutic Targeting of SPINK1-Positive Prostate Cancer. Science Translational Medicine, 2011, 3, 72ra17.	5.8	140
322	Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nature Biotechnology, 2011, 29, 742-749.	9.4	950
323	Magic Angle Spinning NMR-Based Metabolic Profiling of Head and Neck Squamous Cell Carcinoma Tissues. Journal of Proteome Research, 2011, 10, 5232-5241.	1.8	97
324	Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets. Cancer Discovery, 2011, 1, 487-495.	7.7	725

#	Article	IF	Citations
325	Targeting of microRNA-142-3p in dendritic cells regulates endotoxin-induced mortality. Blood, 2011, 117, 6172-6183.	0.6	132
326	Metabolism unhinged: IDH mutations in cancer. Nature Medicine, 2011, 17, 291-293.	15.2	144
327	Disruptive Events in the Life of Prostate Cancer. Cancer Cell, 2011, 19, 301-303.	7.7	20
328	Mechanistic Rationale for Inhibition of Poly(ADP-Ribose) Polymerase in ETS Gene Fusion-Positive Prostate Cancer. Cancer Cell, 2011, 19, 664-678.	7.7	397
329	Coordinated Regulation of Polycomb Group Complexes through microRNAs in Cancer. Cancer Cell, 2011, 20, 187-199.	7.7	191
330	RNA-Seq unleashed. Nature Biotechnology, 2011, 29, 599-600.	9.4	23
331	The Emergence of lncRNAs in Cancer Biology. Cancer Discovery, 2011, 1, 391-407.	7.7	1,612
332	Personalized Oncology Through Integrative High-Throughput Sequencing: A Pilot Study. Science Translational Medicine, 2011, 3, 111ra121.	5.8	531
333	Characterization of Bone Metastases from Rapid Autopsies of Prostate Cancer Patients. Clinical Cancer Research, 2011, 17, 3924-3932.	3.2	69
334	Deep sequencing reveals distinct patterns of DNA methylation in prostate cancer. Genome Research, 2011, 21, 1028-1041.	2.4	166
335	TMPRSS2â€“ERG-Mediated Feed-Forward Regulation of Wild-Type ERG in Human Prostate Cancers. Cancer Research, 2011, 71, 5387-5392.	0.4	42
336	Urine TMPRSS2:ERG Fusion Transcript Stratifies Prostate Cancer Risk in Men with Elevated Serum PSA. Science Translational Medicine, 2011, 3, 94ra72.	5.8	313
337	The DEK oncoprotein is a Su(var) that is essential to heterochromatin integrity. Genes and Development, 2011, 25, 673-678.	2.7	82
338	Characterization of KRAS Rearrangements in Metastatic Prostate Cancer. Cancer Discovery, 2011, 1, 35-43.	7.7	91
339	A Comparison of Single Molecule and Amplification Based Sequencing of Cancer Transcriptomes. PLoS ONE, 2011, 6, e17305.	1.1	48
340	Inhibition of Histone Methylation Arrests Ongoing Graft-Versus-Host Diseases in Mice by Selectively Inducing Apoptosis of Alloreactive Effector T Cells. Blood, 2011, 118, 820-820.	0.6	0
341	ETS Gene Aberrations in Atypical Cribriform Lesions of the Prostate. American Journal of Surgical Pathology, 2010, 34, 478-485.	2.1	91
342	Re: Florian Jentzmik, Carsten Stephan, Kurt Miller, et al. Sarcosine in Urine after Digital Rectal Examination Fails as a Marker in Prostate Cancer Detection and Identification of Aggressive Tumours. Eur Urol 2010;58:12â€“8. European Urology, 2010, 58, e29-e30.	0.9	17

#	Article	IF	Citations
343	An Integrated Network of Androgen Receptor, Polycomb, and TMPRSS2-ERG Gene Fusions in Prostate Cancer Progression. Cancer Cell, 2010, 17, 443-454.	7.7	743
344	Development of selected reaction monitoringâ€MS methodology to measure peptide biomarkers in prostate cancer. Proteomics, 2010, 10, 3506-3514.	1.3	20
345	Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nature Medicine, 2010, 16, 793-798.	15.2	436
346	Triggers for genomic rearrangements: insights into genomic, cellular and environmental influences. Nature Reviews Genetics, 2010, 11, 819-829.	7.7	122
347	â€œTopological Significanceâ€•Analysis of Gene Expression and Proteomic Profiles from Prostate Cancer Cells Reveals Key Mechanisms of Androgen Response. PLoS ONE, 2010, 5, e10936.	1.1	31
348	Quantitative Proteomic Profiling of Prostate Cancer Reveals a Role for miR-128 in Prostate Cancer. Molecular and Cellular Proteomics, 2010, 9, 298-312.	2.5	113
349	On the detection and refinement of transcription factor binding sites using ChIP-Seq data. Nucleic Acids Research, 2010, 38, 2154-2167.	6.5	91
350	The role of YAP transcription coactivator in regulating stem cell self-renewal and differentiation. Genes and Development, 2010, 24, 1106-1118.	2.7	621
351	Nrdp1-Mediated Regulation of ErbB3 Expression by the Androgen Receptor in Androgen-Dependent but not Castrate-Resistant Prostate Cancer Cells. Cancer Research, 2010, 70, 5994-6003.	0.4	49
352	Antibody-Based Detection of ERG Rearrangement-Positive Prostate Cancer. Neoplasia, 2010, 12, 590-IN21.	2.3	305
353	ERG Cooperates with Androgen Receptor in Regulating Trefoil Factor 3 in Prostate Cancer Disease Progression. Neoplasia, 2010, 12, 1031-IN22.	2.3	51
354	Chromosomal Aberrations in Solid Tumors. Progress in Molecular Biology and Translational Science, 2010, 95, 55-94.	0.9	26
355	Exploring Clinical Associations Using â€˜-Omicsâ€™ Based Enrichment Analyses. PLoS ONE, 2009, 4, e5203.	1.1	47
356	Nuclear versus Cytoplasmic Localization of Filamin A in Prostate Cancer: Immunohistochemical Correlation with Metastases. Clinical Cancer Research, 2009, 15, 788-796.	3.2	117
357	Development of a Multiplex Quantitative PCR Signature to Predict Progression in Nonâ€“Muscle-Invasive Bladder Cancer. Cancer Research, 2009, 69, 3810-3818.	0.4	33
358	Induced Chromosomal Proximity and Gene Fusions in Prostate Cancer. Science, 2009, 326, 1230-1230.	6.0	334
359	Melanoma Proliferation and Chemoresistance Controlled by the DEK Oncogene. Cancer Research, 2009, 69, 6405-6413.	0.4	127
360	AGTR1 as a therapeutic target in ER-positive and ERBB-negative breast cancer cases. Cell Cycle, 2009, 8, 3794-3795.	1.3	23

#	Article	IF	Citations
361	Prevalence of TMPRSS2-ERG Fusion Prostate Cancer among Men Undergoing Prostate Biopsy in the United States. Clinical Cancer Research, 2009, 15, 4706-4711.	3.2	205
362	AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 10284-10289.	3.3	140
363	Chimeric transcript discovery by paired-end transcriptome sequencing. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 12353-12358.	3.3	302
364	ETS Gene Fusions in Prostate Cancer: From Discovery to Daily Clinical Practice. European Urology, 2009, 56, 275-286.	0.9	332
365	Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression. Modern Pathology, 2009, 22, 1083-1093.	2.9	209
366	Characterization of ETS gene aberrations in select histologic variants of prostate carcinoma. Modern Pathology, 2009, 22, 1176-1185.	2.9	91
367	Transcriptome sequencing to detect gene fusions in cancer. Nature, 2009, 458, 97-101.	13.7	791
368	Tomlins et al. reply. Nature, 2009, 457, E2-E3.	13.7	6
369	Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature, 2009, 457, 910-914.	13.7	1,944
370	An integrative approach to reveal driver gene fusions from paired-end sequencing data in cancer. Nature Biotechnology, 2009, 27, 1005-1011.	9.4	69
371	Treatment-Dependent Androgen Receptor Mutations in Prostate Cancer Exploit Multiple Mechanisms to Evade Therapy. Cancer Research, 2009, 69, 4434-4442.	0.4	190
372	Current affairs in quantitative targeted proteomics: multiple reaction monitoring-mass spectrometry. Briefings in Functional Genomics & Proteomics, 2009, 8, 145-157.	3.8	105
373	Pathway Biomarker Profiling of Localized and Metastatic Human Prostate Cancer Reveal Metastatic and Prognostic Signatures. Journal of Proteome Research, 2009, 8, 3044-3054.	1.8	59
374	New class of microRNA targets containing simultaneous 5â€²-UTR and 3â€²-UTR interaction sites. Genome Research, 2009, 19, 1175-1183.	2.4	398
375	Applications of genetic programming in cancer research. International Journal of Biochemistry and Cell Biology, 2009, 41, 405-413.	1.2	26
376	Androgen Receptor Regulates a Distinct Transcription Program in Androgen-Independent Prostate Cancer. Cell, 2009, 138, 245-256.	13.5	797
377	Oncogenic gene fusions in epithelial carcinomas. Current Opinion in Genetics and Development, 2009, 19, 82-91.	1.5	64
378	A FIRE-y PAGE in the Computational Analysis of Cancer Profiles. Molecular Cell, 2009, 36, 732-733.	4.5	0

#	Article	IF	Citations
379	RHAMM (CD168) Is Overexpressed at the Protein Level and May Constitute an Immunogenic Antigen in Advanced Prostate Cancer Disease. Neoplasia, 2009, 11, 956-963.	2.3	76
380	The Discovery of Common Recurrent Transmembrane Protease Serine 2 (TMPRSS2)-Erythroblastosis Virus E26 Transforming Sequence (ETS) Gene Fusions in Prostate Cancer. Advances in Anatomic Pathology, 2009, 16, 145-153.	2.4	47
381	Proteomic Interrogation of Androgen Action in Prostate Cancer Cells Reveals Roles of Aminoacyl tRNA Synthetases. PLoS ONE, 2009, 4, e7075.	1.1	54
382	Fas-mediated T cell deletion potentiates tumor antigen-specific tolerance in a mouse model of prostate cancer. Cancer Immunology, Immunotherapy, 2008, 57, 1357-1365.	2.0	4
383	CCL2 induces prostate cancer transendothelial cell migration via activation of the small GTPase Rac. Journal of Cellular Biochemistry, 2008, 104, 1587-1597.	1.2	46
384	The discovery and application of gene fusions in prostate cancer. BJU International, 2008, 102, 276-282.	1.3	39
385	The Role of SPINK1 in ETS Rearrangement-Negative Prostate Cancers. Cancer Cell, 2008, 13, 519-528.	7.7	303
386	CXCL5 Promotes Prostate Cancer Progression. Neoplasia, 2008, 10, 244-254.	2.3	122
387	Recurrent gene fusions in prostate cancer. Nature Reviews Cancer, 2008, 8, 497-511.	12.8	617
388	Inhibition of CCN6 (Wnt-1-Induced Signaling Protein 3) Down-Regulates E-Cadherin in the Breast Epithelium through Induction of Snail and ZEB1. American Journal of Pathology, 2008, 172, 893-904.	1.9	60
389	Role of the TMPRSS2-ERG Gene Fusion in Prostate Cancer. Neoplasia, 2008, 10, 177-IN9.	2.3	608
390	Golgi Protein GOLM1 Is a Tissue and Urine Biomarker of Prostate Cancer. Neoplasia, 2008, 10, 1285-IN35.	2.3	89
391	A Transcriptional Fingerprint of Estrogen in Human Breast Cancer Predicts Patient Survival. Neoplasia, 2008, 10, 79-IN34.	2.3	32
392	EML4-ALK Fusion Lung Cancer: A Rare Acquired Event. Neoplasia, 2008, 10, 298-302.	2.3	231
393	Genomic Loss of microRNA-101 Leads to Overexpression of Histone Methyltransferase EZH2 in Cancer. Science, 2008, 322, 1695-1699.	6.0	995
394	A First-Generation Multiplex Biomarker Analysis of Urine for the Early Detection of Prostate Cancer. Cancer Research, 2008, 68, 645-649.	0.4	369
395	Characterization of TMPRSS2-ETS Gene Aberrations in Androgen-Independent Metastatic Prostate Cancer. Cancer Research, 2008, 68, 3584-3590.	0.4	249
396	A Fluorescence In situ Hybridization Screen for E26 Transformationâ€“Specific Aberrations: Identification of DDX5-ETV4 Fusion Protein in Prostate Cancer. Cancer Research, 2008, 68, 7629-7637.	0.4	139

#	Article	IF	Citations
397	Humoral Response Profiling Reveals Pathways to Prostate Cancer Progression. Molecular and Cellular Proteomics, 2008, 7, 600-611.	2.5	54
398	Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 Gene Fusions in Prostate Cancer. Cancer Research, 2008, 68, 73-80.	0.4	244
399	Estrogen-Dependent Signaling in a Molecularly Distinct Subclass of Aggressive Prostate Cancer. Journal of the National Cancer Institute, 2008, 100, 815-825.	3.0	286
400	Genomic outlier profile analysis: mixture models, null hypotheses, and nonparametric estimation. Biostatistics, 2008, 10, 60-69.	0.9	28
401	TEAD mediates YAP-dependent gene induction and growth control. Genes and Development, 2008, 22, 1962-1971.	2.7	1,943
402	AZGP1 Autoantibody Predicts Survival and Histone Deacetylase Inhibitors Increase Expression in Lung Adenocarcinoma. Journal of Thoracic Oncology, 2008, 3, 1236-1244.	0.5	47
403	KLF6-SV1 overexpression accelerates human and mouse prostate cancer progression and metastasis. Journal of Clinical Investigation, 2008, 118, 2711-2721.	3.9	97
404	An expression signature of estrogen-regulated genes predicts disease-free survival in tamoxifen-treated patients better than progesterone receptor status. Transactions of the American Clinical and Climatological Association, 2008, 119, 77-90; discussion 90-2.	0.9	11
405	Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes and Development, 2007, 21, 2747-2761.	2.7	2,487
406	From Bytes to Bedside: Data Integration and Computational Biology for Translational Cancer Research. PLoS Computational Biology, 2007, 3, e12.	1.5	52
407	Bioinformatics Approaches in the Study of Cancer. Current Molecular Medicine, 2007, 7, 133-141.	0.6	73
408	Integrating Biomedical Knowledge to Model Pathways of Prostate Cancer Progression. Cell Cycle, 2007, 6, 1177-1187.	1.3	12
409	A Polycomb Repression Signature in Metastatic Prostate Cancer Predicts Cancer Outcome. Cancer Research, 2007, 67, 10657-10663.	0.4	308
410	Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 19488-19493.	3.3	171
411	Integrative Analysis of Genomic Aberrations Associated with Prostate Cancer Progression. Cancer Research, 2007, 67, 8229-8239.	0.4	103
412	Autoantibody Profiles Reveal Ubiquilin 1 as a Humoral Immune Response Target in Lung Adenocarcinoma. Cancer Research, 2007, 67, 3461-3467.	0.4	86
413	TMPRSS2-ERG Fusion Prostate Cancer: An Early Molecular Event Associated With Invasion. American Journal of Surgical Pathology, 2007, 31, 882-888.	2.1	394
414	A Hierarchical Network of Transcription Factors Governs Androgen Receptor-Dependent Prostate Cancer Growth. Molecular Cell, 2007, 27, 380-392.	4.5	598

#	Article	IF	Citations
415	Heterogeneity of TMPRSS2 Gene Rearrangements in Multifocal Prostate Adenocarcinoma: Molecular Evidence for an Independent Group of Diseases. Cancer Research, 2007, 67, 7991-7995.	0.4	197
416	Oncomine 3.0: Genes, Pathways, and Networks in a Collection of 18,000 Cancer Gene Expression Profiles. Neoplasia, 2007, 9, 166-180.	2.3	1,847
417	Molecular Concepts Analysis Links Tumors, Pathways, Mechanisms, and Drugs. Neoplasia, 2007, 9, 443-IN9.	2.3	124
418	Molecular Characterization of TMPRSS2-ERG Gene Fusion in the NCI-H660 Prostate Cancer Cell Line: A New Perspective for an Old Model. Neoplasia, 2007, 9, 200-IN3.	2.3	119
419	The Lethal Phenotype of Cancer: The Molecular Basis of Death Due to Malignancy. Ca-A Cancer Journal for Clinicians, 2007, 57, 225-241.	157.7	145
420	Feature Selection and Molecular Classification of Cancer Using Genetic Programming. Neoplasia, 2007, 9, 292-IN3.	2.3	68
421	Empirical Bayes Identication of Tumor Progression Genes from Microarray Data. Biometrical Journal, 2007, 49, 68-77.	0.6	0
422	Integrative molecular concept modeling of prostate cancer progression. Nature Genetics, 2007, 39, 41-51.	9.4	837
423	Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Modern Pathology, 2007, 20, 538-544.	2.9	281
424	Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature, 2007, 448, 595-599.	13.7	743
425	Integrative Genomics Analysis Reveals Silencing of Î²-Adrenergic Signaling by Polycomb in Prostate Cancer. Cancer Cell, 2007, 12, 419-431.	7.7	204
426	The Registry Case Finding Engine: An Automated Tool to Identify Cancer Cases from Unstructured, Free-Text Pathology Reports and Clinical Notes. Journal of the American College of Surgeons, 2007, 205, 690-697.	0.2	26
427	Differential Phosphoprotein Mapping in Cancer Cells Using Protein Microarrays Produced from 2-D Liquid Fractionation. Analytical Chemistry, 2006, 78, 702-710.	3.2	29
428	Defining Aggressive Prostate Cancer Using a 12-Gene Model. Neoplasia, 2006, 8, 59-68.	2.3	90
429	ADAM15 Disintegrin Is Associated with Aggressive Prostate and Breast Cancer Disease. Neoplasia, 2006, 8, 319-329.	2.3	85
430	Noninvasive Detection of TMPRSS2:ERG Fusion Transcripts in the Urine of Men with Prostate Cancer. Neoplasia, 2006, 8, 885-888.	2.3	212
431	Whole Transcriptome Amplification for Gene Expression Profiling and Development of Molecular Archives. Neoplasia, 2006, 8, 153-162.	2.3	40
432	TMPRSS2:ETV4 Gene Fusions Define a Third Molecular Subtype of Prostate Cancer. Cancer Research, 2006, 66, 3396-3400.	0.4	432

#	Article	IF	Citations
433	Cancer immunomics: Using autoantibody signatures in the early detection of prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2006, 24, 237-242.	0.8	45
434	Molecular markers of prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2006, 24, 538-551.	0.8	66
435	Metastasis suppressor gene Raf kinase inhibitor protein (RKIP) is a novel prognostic marker in prostate cancer. Prostate, 2006, 66, 248-256.	1.2	197
436	A SLAMS dunk for cancer regulators. Nature Biotechnology, 2006, 24, 524-526.	9.4	0
437	Bioinformatics approach leads to the discovery of the TMPRSS2:ETS gene fusion in prostate cancer. Laboratory Investigation, 2006, 86, 1099-1102.	1.7	35
438	Of mice and men: Cancer gene discovery using comparative oncogenomics. Cancer Cell, 2006, 10, 2-4.	7.7	10
439	Enhancing the antitumor activity of ErbB blockade with histone deacetylase (HDAC) inhibition. International Journal of Cancer, 2006, 118, 1041-1050.	2.3	41
440	Selection and cloning of poly(rC)-binding protein 2 and Raf kinase inhibitor protein RNA activators of 2â€²,5â€²-oligoadenylate synthetase from prostate cancer cells. Nucleic Acids Research, 2006, 34, 6684-6695.	6.5	48
441	Trisomy 12-associated, t(11;14)-negative mature B-cell leukemia with gene expression profile resembling mantle cell lymphoma. Leukemia and Lymphoma, 2006, 47, 121-127.	0.6	3
442	TMPRSS2:ERG Fusion-Associated Deletions Provide Insight into the Heterogeneity of Prostate Cancer. Cancer Research, 2006, 66, 8337-8341.	0.4	475
443	Nod1 acts as an intracellular receptor to stimulate chemokine production and neutrophil recruitment in vivo. Journal of Experimental Medicine, 2006, 203, 203-213.	4.2	199
444	A Systems Approach to Model Metastatic Progression: Figure 1.. Cancer Research, 2006, 66, 5537-5539.	0.4	9
445	Delineation, Functional Validation, and Bioinformatic Evaluation of Gene Expression in Thyroid Follicular Carcinomas with the PAX8-PPARG Translocation. Clinical Cancer Research, 2006, 12, 1983-1993.	3.2	125
446	Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells. Molecular Cancer Therapeutics, 2006, 5, 3096-3104.	1.9	115
447	Ataxia Telangiectasia Mutated Down-regulates Phospho-Extracellular Signal-Regulated Kinase 1/2 via Activation of MKP-1 in Response to Radiation. Cancer Research, 2006, 66, 11554-11559.	0.4	25
448	Identification of EZH2 as a Molecular Marker for a Precancerous State in Morphologically Normal Breast Tissues. Cancer Research, 2006, 66, 4095-4099.	0.4	120
449	Activation of Mitogen-Activated Protein Kinase in Estrogen Receptor Î±â€“Positive Breast Cancer Cells In vitro Induces an In vivo Molecular Phenotype of Estrogen Receptor Î±â€“Negative Human Breast Tumors. Cancer Research, 2006, 66, 3903-3911.	0.4	226
450	Purification of an MLL Partner Associated Complex (MPAC) Suggests a Common Role for MLL Fusion Partners in Transcriptional Elongation.. Blood, 2006, 108, 770-770.	0.6	2

#	Article	IF	Citations
451	Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer. Science, 2005, 310, 644-648.	6.0	3,541
452	Probabilistic model of the human protein-protein interaction network. Nature Biotechnology, 2005, 23, 951-959.	9.4	380
453	Mining for regulatory programs in the cancer transcriptome. Nature Genetics, 2005, 37, 579-583.	9.4	158
454	Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell, 2005, 8, 393-406.	7.7	731
455	Covariate adjustment in the analysis of microarray data from clinical studies. Functional and Integrative Genomics, 2005, 5, 18-27.	1.4	11
456	Classification and Selection of Biomarkers in Genomic Data Using LASSO. Journal of Biomedicine and Biotechnology, 2005, 2005, 147-154.	3.0	99
457	Serum Antibodies to Huntingtin Interacting Protein-1: A New Blood Test for Prostate Cancer. Cancer Research, 2005, 65, 4126-4133.	0.4	54
458	Identification of GATA3 as a Breast Cancer Prognostic Marker by Global Gene Expression Meta-analysis. Cancer Research, 2005, 65, 11259-11264.	0.4	272
459	The Unfolded Protein Response Modulates Toxicity of the Expanded Glutamine Androgen Receptor*. Journal of Biological Chemistry, 2005, 280, 21264-21271.	1.6	53
460	Mechanisms of Enhanced Radiation Response following Epidermal Growth Factor Receptor Signaling Inhibition by Erlotinib (Tarceva). Cancer Research, 2005, 65, 3328-3335.	0.4	359
461	A Germline DNA Polymorphism Enhances Alternative Splicing of the KLF6 Tumor Suppressor Gene and Is Associated with Increased Prostate Cancer Risk. Cancer Research, 2005, 65, 1213-1222.	0.4	202
462	Development of an Internally Controlled Antibody Microarray. Molecular and Cellular Proteomics, 2005, 4, 1664-1672.	2.5	37
463	The Polycomb Group Protein EZH2 Impairs DNA Repair in Breast Epithelial Cells. Neoplasia, 2005, 7, 1011-1019.	2.3	86
464	Autoantibody Signatures in Prostate Cancer. New England Journal of Medicine, 2005, 353, 1224-1235.	13.9	581
465	Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 9309-9314.	3.3	874
466	Radiosensitization by Pan ErbB Inhibitor CI-1033 in Vitro and in Vivo. Clinical Cancer Research, 2004, 10, 691-700.	3.2	85
467	The Role of Metastasis-Associated Protein 1 in Prostate Cancer Progression. Cancer Research, 2004, 64, 825-829.	0.4	126
468	Overexpression, Amplification, and Androgen Regulation of TPD52 in Prostate Cancer. Cancer Research, 2004, 64, 3814-3822.	0.4	145

#	Article	IF	Citations
469	JAGGED1 Expression Is Associated with Prostate Cancer Metastasis and Recurrence. Cancer Research, 2004, 64, 6854-6857.	0.4	310
470	Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases. Cancer Research, 2004, 64, 9209-9216.	0.4	816
471	Integration of high-resolution array comparative genomic hybridization analysis of chromosome 16q with expression array data refines common regions of loss at 16q23â€“qter and identifies underlying candidate tumor suppressor genes in prostate cancer. Oncogene, 2004, 23, 3487-3494.	2.6	78
472	RhoC Induces Differential Expression of Genes Involved in Invasion and Metastasis in MCF10A Breast Cells. Breast Cancer Research and Treatment, 2004, 84, 3-12.	1.1	69
473	Bioinformatics Strategies for Translating Genome-Wide Expression Analyses into Clinically Useful Cancer Markers. Annals of the New York Academy of Sciences, 2004, 1020, 32-40.	1.8	53
474	Humoral Immune Response to Â-Methylacyl-CoA Racemase and Prostate Cancer. Journal of the National Cancer Institute, 2004, 96, 834-843.	3.0	121
475	Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors. Human Molecular Genetics, 2004, 13, 1303-1313.	1.4	171
476	ONCOMINE: A Cancer Microarray Database and Integrated Data-Mining Platform. Neoplasia, 2004, 6, 1-6.	2.3	3,212
477	Expression of the Platelet-Derived Growth Factor Receptor in Prostate Cancer and Treatment Implications with Tyrosine Kinase Inhibitors. Neoplasia, 2004, 6, 503-512.	2.3	49
478	Elevated Î±-Methylacyl-CoA Racemase Enzymatic Activity in Prostate Cancer. American Journal of Pathology, 2004, 164, 787-793.	1.9	68
479	Quantitative Determination of Expression of the Prostate Cancer Protein Î±-Methylacyl-CoA Racemase Using Automated Quantitative Analysis (AQUA). American Journal of Pathology, 2004, 164, 831-840.	1.9	145
480	C5a-Induced Gene Expression in Human Umbilical Vein Endothelial Cells. American Journal of Pathology, 2004, 164, 849-859.	1.9	152
481	FIZZ1 Stimulation of Myofibroblast Differentiation. American Journal of Pathology, 2004, 164, 1315-1326.	1.9	168
482	Statistical issues and methods for meta-analysis of microarray data: a case study in prostate cancer. Functional and Integrative Genomics, 2003, 3, 180-188.	1.4	79
483	Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. Journal of Cellular Biochemistry, 2003, 89, 462-473.	1.2	405
484	Prostate cancer biomarkers: a current perspective. Expert Review of Molecular Diagnostics, 2003, 3, 459-470.	1.5	14
485	Dysregulation of the Annexin Family Protein Family Is Associated with Prostate Cancer Progression. American Journal of Pathology, 2003, 162, 255-261.	1.9	162
486	Development of Human Protein Reference Database as an Initial Platform for Approaching Systems Biology in Humans. Genome Research, 2003, 13, 2363-2371.	2.4	954

#	Article	IF	Citations
487	The Role of Calpain in the Proteolytic Cleavage of E-cadherin in Prostate and Mammary Epithelial Cells. Journal of Biological Chemistry, 2003, 278, 1372-1379.	1.6	146
488	EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 11606-11611.	3.3	1,482
489	Multiplex Biomarker Approach for Determining Risk of Prostate-Specific Antigen-Defined Recurrence of Prostate Cancer. Journal of the National Cancer Institute, 2003, 95, 661-668.	3.0	249
490	Diagnostic usefulness of monoclonal antibody P504S in the workup of atypical prostatic glandular proliferations. American Journal of Clinical Pathology, 2003, 120, 737-45.	0.4	9
491	Transcriptome analysis of HER2 reveals a molecular connection to fatty acid synthesis. Cancer Research, 2003, 63, 132-9.	0.4	151
492	The role of an 80 kDa fragment of E-cadherin in the metastatic progression of prostate cancer. Clinical Cancer Research, 2003, 9, 6447-52.	3.2	69
493	Molecular Cross-talk between the TRAIL and Interferon Signaling Pathways. Journal of Biological Chemistry, 2002, 277, 575-585.	1.6	89
494	Î±-Methylacyl Coenzyme A Racemase as a Tissue Biomarker for Prostate Cancer. JAMA - Journal of the American Medical Association, 2002, 287, 1662.	3.8	565
495	Gene-Expression Profiles in Hereditary Breast Cancer. Advances in Anatomic Pathology, 2002, 9, 1-6.	2.4	6
496	Alpha-Methylacyl-CoA Racemase. American Journal of Surgical Pathology, 2002, 26, 926-931.	2.1	274
497	Î±-Methylacyl-CoA Racemase: Expression Levels of this Novel Cancer Biomarker Depend on Tumor Differentiation. American Journal of Pathology, 2002, 161, 841-848.	1.9	121
498	Changes in Differential Gene Expression because of Warm Ischemia Time of Radical Prostatectomy Specimens. American Journal of Pathology, 2002, 161, 1743-1748.	1.9	138
499	DNA Microarrays: Implications for Clinical Medicine. Journal of Investigative Surgery, 2002, 15, 275-279.	0.6	13
500	A functional thrombin receptor (PAR1) is expressed on bone-derived prostate cancer cell lines. Urology, 2002, 60, 760-765.	0.5	90
501	Using Protein Microarrays to Study Cancer. BioTechniques, 2002, 33, S46-S53.	0.8	22
502	The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature, 2002, 419, 624-629.	13.7	2,411
503	High and selective expression of yeast cytosine deaminase under a carcinoembryonic antigen promoter-enhancer. Cancer Research, 2002, 62, 2337-42.	0.4	29
504	Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Research, 2002, 62, 4427-33.	0.4	511

#	Article	IF	Citations
505	Protein microarrays: a powerful tool to study cancer. Current Opinion in Molecular Therapeutics, 2002, 4, 587-93.	2.8	1
506	Molecular Signatures of Sepsis. American Journal of Pathology, 2001, 159, 1199-1209.	1.9	190
507	Delineation of prognostic biomarkers in prostate cancer. Nature, 2001, 412, 822-826.	13.7	1,551
508	The Apoptosome: Heart and Soul of the Cell Death Machine. Neoplasia, 1999, 1, 5-15.	2.3	182
509	A Caspase-Resistant Form of Bcl-XL, but Not Wild Type Bcl-XL, Promotes Clonogenic Survival After Ionizing Radiation. Neoplasia, 1999, 1, 63-70.	2.3	11
510	A Role for FADD in T Cell Activation and Development. Immunity, 1998, 8, 439-449.	6.6	236
511	The Death Inhibitory Molecules CED-9 and CED-4L Use a Common Mechanism to Inhibit the CED-3 Death Protease. Journal of Biological Chemistry, 1998, 273, 17708-17712.	1.6	31
512	Ultraviolet Radiation-induced Apoptosis Is Mediated by Activation of CD-95 (Fas/APO-1). Journal of Biological Chemistry, 1997, 272, 25783-25786.	1.6	273
513	The Receptor for the Cytotoxic Ligand TRAIL. Science, 1997, 276, 111-113.	6.0	1,665
514	Portrait of an executioner: the molecular mechanism of Fas/APO-1-induced apoptosis. Seminars in Immunology, 1997, 9, 69-76.	2.7	95
515	Keystone 1997: Return of the worm. Cell Death and Differentiation, 1997, 4, 519-521.	5.0	0
516	The inhibition of pro-apoptotic ICE-like proteases enhances HIV replication. Nature Medicine, 1997, 3, 333-337.	15.2	86
517	Role of CED-4 in the activation of CED-3. Nature, 1997, 388, 728-729.	13.7	185
518	ICE-LAP3, a Novel Mammalian Homologue of the Caenorhabditis elegans Cell Death Protein Ced-3 Is Activated during Fas- and Tumor Necrosis Factor-induced Apoptosis. Journal of Biological Chemistry, 1996, 271, 1621-1625.	1.6	266
519	FLICE, A Novel FADD-Homologous ICE/CED-3â€“like Protease, Is Recruited to the CD95 (Fas/APO-1) Death-Inducing Signaling Complex. Cell, 1996, 85, 817-827.	13.5	2,944
520	Signal Transduction by DR3, a Death Domain-Containing Receptor Related to TNFR-1 and CD95. Science, 1996, 274, 990-992.	6.0	625
521	ICE-LAP6, a Novel Member of the ICE/Ced-3 Gene Family, Is Activated by the Cytotoxic T Cell Protease Granzyme B. Journal of Biological Chemistry, 1996, 271, 16720-16724.	1.6	246
522	The cell-death machine. Current Biology, 1996, 6, 555-562.	1.8	358

#	Article	IF	Citations
523	Cytotoxic T-cell-derived granzyme B activates the apoptotic protease ICE-LAP3. Current Biology, 1996, 6, 897-899.	1.8	103
524	Molecular Ordering of the Cell Death Pathway. Journal of Biological Chemistry, 1996, 271, 4573-4576.	1.6	536
525	FADD/MORT1 Is a Common Mediator of CD95 (Fas/APO-1) and Tumor Necrosis Factor Receptor-induced Apoptosis. Journal of Biological Chemistry, 1996, 271, 4961-4965.	1.6	680
526	FADD, a novel death domain-containing protein, interacts with the death domain of fas and initiates apoptosis. Cell, 1995, 81, 505-512.	13.5	2,298